At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
L-ascorbic acid +1 moredrug
Likely dose
L-ascorbic acid 50 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
In Brief
A Phase 2 clinical trial evaluating L-ascorbic acid and Placebo for COVID-19 and 2 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This study will evaluate the safety of a 96-hour intravenous vitamin C infusion protocol (50 mg/kg every 6 hours) in patients with hypoxemia and suspected COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Lung Injury, Acute, Kidney Injury
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartDec 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 14, 2020
Enrollment StartDec 18, 2020
Primary CompletionJun 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.2 years ago
Interventions
L-ascorbic aciddrug
50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
Placeboother
Dextrose 5% Water